GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · Real-Time Price · USD
0.410
+0.027 (7.16%)
At close: Nov 4, 2024, 4:00 PM
0.392
-0.018 (-4.44%)
Pre-market: Nov 5, 2024, 9:20 AM EST
GlycoMimetics Employees
GlycoMimetics had 35 employees as of December 31, 2023. The number of employees decreased by 4 or -10.26% compared to the previous year.
Employees
35
Change (1Y)
-4
Growth (1Y)
-10.26%
Revenue / Employee
$286
Profits / Employee
-$1,117,521
Market Cap
26.44M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Beyond Air | 107 |
Athira Pharma | 67 |
PolyPid | 62 |
Pieris Pharmaceuticals | 50 |
Palatin Technologies | 30 |
Unity Biotechnology | 19 |
NeuroBo Pharmaceuticals | 8 |
XTL Biopharmaceuticals | 7 |
GLYC News
- 4 days ago - GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC - Business Wire
- 6 days ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - PRNewsWire
- 7 days ago - GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire
- 7 days ago - GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - Business Wire
- 3 months ago - GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan - Business Wire
- 5 months ago - GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - Business Wire
- 5 months ago - GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 - Business Wire
- 6 months ago - GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript - Seeking Alpha